Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Bifidobacterium longum BB536 and Reduced Fever Incidence

Doses used in studies

CFU/day: 100 billion (median 100 billion, IQR 100 billion–100 billion) — 1 study

Time to effect

Median: 3.3 months · IQR 3.3 months–3.3 months · Range 3.3 months–3.3 months — Reported in 1 of 1 study

1 of 1 paper

Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly.
- 2010-05-23
- RCT
- Bioscience, biotechnology, and biochemistry 74(5)
- - Kazuyoshi Namba
  - Michiko Hatano
  - Tomoko Yaeshima
  - Mitsunori Takase
  - Kunihiko Suzuki
- PubMed: 20460726
- DOI: 10.1271/bbb.90749
5 Insights on
- Reduced Fever Incidence
- High evidence
- Elderly
The proportion of subjects with fever was also significantly lower in the BB536 group than in the placebo group.
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
1 x 10^11 CFU daily